The Blood-based Biopsy Tests (BBB) are based on the molecular detection of Circulating Tumor Cells (CTCs) as a measure of therapy efficacy and recurrence of cancer. The presence, abundance and molecular characteristics of CTCs are analyzed by immunofluorescense staining and automated image analysis and by quantification of RNA biomarkers specific for each type of cancer. A comprehensive, fast, most accurate, near-patient CTC detection, enumeration and molecular characterization system will be offered. A test for the detection and enumeration of Circulating Endothelial Cells (CECs) allows for investigating the damaging effect of several diseases on the vascular epithelium and its diagnostic impact. Another test detects Circulating Stromal Cells (CSCs) which are indicative for endometrial diseases. CSCs are a potential diagnostic target.
Most of OncoLab's Dx4U tests are in vitro diagnostic tests and are CE-IVD marked. Modified versions of the test will be available for research applications (RUO marked).
First products for the detection of CTCs, CECs, and CSCs will be launched in 2020.
Our BBB tests provide reliable information
» to stop ineffective treatment early on, avoiding unnecessary side effects which are a heavy burden for the patient;
» to choose an alternative, more effective therapy;
» to detect cancer relapse earlier than any other currently available method, enabling earliest possible onset of treatment.